🚨 Trade Update: RKLB — Both Price Targets Hit in 4 Days ✅
We recommended Rocket Lab USA (NASDAQ: RKLB) on May 11, 2026, at a buy level of $106.50, with price targets of $122.00 (PT1) and $130.00 (PT2) and a stop-loss at $98.50 on a closing basis.
Both targets have been achieved — the stock is currently trading around $132.55, comfortably above PT2. For those still holding, traders with a higher risk appetite may consider using $130 (our PT2) as a trailing stop-loss, locking in gains while leaving room for further upside.
Bottom line: A clean +22% trade hit in just 4 days — both targets in hand, with PT2 now serving as a logical trailing stop for those riding the remaining momentum.
🚨 Trade Update: MARA — PT1 Achieved, +37% ✅
We recommended MARA Holdings (NASDAQ: MARA) on April 6, 2026, at a buy level of $9.10, with price targets of $12.50 (PT1) and $15.00 (PT2). The first target has been hit, and the stock is currently trading at $13.29 — a 46% gain from our entry.
With the trade already delivering over 2x the risk taken, conservative traders may consider trimming half their position here to lock in profits. Those looking to ride the remaining momentum can hold for PT2 with a trailing stop-loss at $10.70 on a closing basis.
Bottom line: PT1 in hand at +37%; the trade is already up 46% from entry. Trim half here, or trail toward PT2 with a $10.70 closing stop.
Cellebrite DI (NASDAQ: CLBT) is setting up for a powerful breakout.
As we’ll get to just ahead, the combination of a record Q1 earnings beat with raised guidance, a landmark FedRAMP High federal authorization, and a fresh technical reversal setup makes CLBT one of the more interesting setups on the board. Here’s what’s going on…
The Themes Behind the Move
Cellebrite is a digital-investigations software company that builds the platforms used by law enforcement, government agencies, and corporate security teams to legally access, extract, analyze, and manage digital evidence — from smartphones, drones, cloud accounts, and IoT devices — across the entire investigative lifecycle.
In plain English, when police, federal agencies, or corporate security teams seize a phone, a laptop, or a drone tied to a case — whether it’s organized crime, child exploitation, terrorism, financial fraud, or national security — Cellebrite’s software is what unlocks the device, pulls the data, maps the connections, and turns weeks of manual forensic work into hours. Its business hinges on subscription/ARR growth, federal and government cloud adoption, the traction of its new AI products like Genesis and Guardian Investigate, and staying ahead of competitors as device security and criminal tradecraft evolve.
CLBT’s latest move reflects a powerful confluence of developments — financial, regulatory, and product — that have come together in rapid succession to fundamentally reframe the company’s near-term growth trajectory.
| Theme / Catalyst | What Happened | Why Traders Care |
|---|---|---|
| Record Q1 2026 beat + raised guidance | On May 14, Cellebrite reported Q1 revenue of $128.3 million (+19% YoY), subscription revenue of $117.9 million (+23% YoY), ARR of $493 million (+21% YoY), and non-GAAP EPS of $0.12 (beating estimates). 2026 guidance was reaffirmed at revenue of $565–571M, ARR of $567–573M, and adjusted EBITDA of $149–155M. | A beat-and-raise quarter validates the subscription pivot and confirms that ARR is accelerating, not just maintaining — a key signal for software-multiple expansion. |
| FedRAMP High federal authorization | Cellebrite Government Cloud achieved FedRAMP High authorization in early May — the “gold standard” for U.S. federal cloud security. This unlocks compliant access for federal agencies to use Cellebrite’s cloud-based solutions like Guardian for their most sensitive data. | FedRAMP High removes the single biggest compliance barrier to federal adoption and opens the door to material fiscal 2027 federal budget allocations — a structural, long-term moat that competitors can’t easily replicate. |
| Agentic AI product momentum | Spring 2026 brought early access to Cellebrite Genesis — an agentic AI tool that drew 500+ registered users across 15 countries in eight weeks versus management’s expectation of “one or two dozen.” Other launches included Guardian Investigate (AI-powered investigative nerve center) and the SCG Canada acquisition for drone forensics. | Genesis turns weeks of manual evidence triage into minutes, repositioning CLBT from a tool vendor to a high-value AI platform — and the explosive early adoption suggests material monetization upside once general availability lands. |
| Sector tailwinds | The broader law enforcement software market is projected to reach $19 billion in 2026, driven by exploding digital-evidence volumes and an “AI threat multiplier” — criminal networks using GenAI for fraud, deepfakes, and automated attacks are forcing law enforcement into a mandatory tech-upgrade cycle. | Digital forensics has shifted from a discretionary IT line item to a non-discretionary budget priority — virtually every modern investigation now hinges on digital evidence, and agencies are buyers, not browsers. |
| Strengthened fundamentals | CLBT posted GAAP gross margin of 82.5% (non-GAAP 85.9%) and trailing-twelve-month free cash flow of $158.6 million — a robust 32% FCF margin. Management also raised the 2026 ARR outlook to $567–573 million. | Software-grade margins, strong cash generation, and rising recurring revenue give CLBT the financial flexibility to invest in AI without dilution — a rare profile in the AI-spend cycle. |
| Analyst coverage | Among the 5 analysts covering CLBT, the average 12-month price target sits at $22.50, with a high of $25.00 and a low of $18.00 — implying roughly 71% upside to the mean and as much as 91% upside on the high end from recent levels. Coverage includes Needham, TD Cowen, Lake Street, and J.P. Morgan, with recent commentary remaining bullish on ARR momentum, the AI moat, and federal upside. | Even the lowest analyst target sits well above the current price — a setup that gives the breakout meaningful headroom before it would even hit the bearish end of Wall Street’s range. |
| Upcoming triggers | Traders are watching the mid-June 2026 General Availability launch of Genesis (the shift from free trials to paid monetization), a packed slate of investor conferences through May and June (J.P. Morgan, TD Cowen, Craig-Hallum, William Blair, Mizuho, D.A. Davidson), and Q2 2026 earnings in August. | A staggered set of high-conviction catalysts — Genesis monetization, conference-driven AI updates, federal traction commentary, and Q2 earnings — each of which can independently move the stock through year-end. |
If needed, swipe or scroll sideways to view the full table.
Put it all together, and CLBT is looking less like a niche mobile-forensics vendor and more like a commercially executing AI-driven digital-investigations platform with accelerating ARR, federal moat expansion, and software-grade margins underwriting the next leg of growth.
The story is getting stronger by the week, but the chart is what could determine whether this move has more room to run in the near term. Here are the bullish technical signals traders should be watching now.
Bullish Technical Signals
#1 Downtrend Channel Breakout Attempt: CLBT has been confined within a well-defined downtrend channel since late 2025, with a series of lower highs and lower lows compressing price from roughly $20 down to the $11 range. The stock is now pushing off the lower rail of that channel on notably elevated volume — the most convincing buying volume we’ve seen in several weeks. A decisive breakout above the upper rail (currently near $14.50–$15) would negate the multi-month downtrend structure entirely and open the path toward a measured move back into the mid-to-upper teens. Even before a confirmed breakout, the higher-volume bounce off channel support suggests sellers are losing grip at these levels.
CLBT – Daily Chart
#2 Bullish Stochastic: On the daily chart, the %K line has crossed above the %D line while both were still embedded in oversold territory (below 20). This is the highest-conviction variant of a stochastic signal — a crossover that originates within the oversold zone rather than merely near it. It indicates that downside momentum has been exhausted and fresh buying interest is stepping in. The %K line is now accelerating away from %D, suggesting the early stages of a momentum shift rather than a brief dead-cat bounce.
#3 Rising OBV with Bullish Divergence: The daily chart shows that OBV has been trending higher even as price was still basing near its lows — a textbook bullish divergence. When volume on up-days consistently outpaces volume on down-days while price remains flat or depressed, it often signals stealth accumulation. Smart money appears to be building positions ahead of a move. This divergence between rising OBV and subdued price action adds conviction that the next meaningful move is more likely up than down.
#4 Above Support Area: On the weekly chart, CLBT has bounced off a former resistance zone near $12.40 (marked by the pink dotted line) that has now flipped to support — a classic polarity shift. This level was tested in April and held, forming a higher low relative to the March trough around $11. The market’s ability to reclaim and hold this zone as a floor reflects a meaningful shift in market structure — former sellers have become buyers.
CLBT – Weekly Chart
#5 Price Above 200-Week SMA: Crucially, CLBT is also trading above its 200-week simple moving average, which acts as a long-term trend anchor. Stocks that hold above their 200-week SMA after a pullback tend to be in secular uptrends experiencing cyclical corrections, not structural breakdowns. This weekly support confluence — polarity-flip zone plus 200-week SMA — gives the setup a strong macro foundation.
#6 Bullish Parabolic SAR Flip: The weekly Parabolic SAR dots have flipped from above price to below it — a formal trend-reversal signal. This flip is particularly meaningful on the weekly timeframe, where it filters out the noise of daily fluctuations. The SAR dots now serve as a dynamic trailing stop: as long as price remains above the dots, the weekly trend bias stays bullish. A SAR flip combined with the support hold and OBV divergence creates a layered confirmation that the intermediate-term trend is turning.
#7 Recovery From Oversold RSI: The weekly RSI has lifted off the low-40s range, just above oversold territory. While it hasn’t yet crossed the 50 midline — which would confirm bullish momentum — the direction is encouraging. RSI recovering from near-oversold levels on the weekly chart has historically marked the early innings of multi-week rallies in CLBT. A push above 50 on the RSI would serve as additional confirmation that the balance of power has shifted from sellers to buyers.
Risks to Consider
Even strong setups can fail, especially in a software/digital-forensics name like Cellebrite. A few things could knock the stock off course:
- A breakdown back below the downtrend channel support and the $12.40 weekly support zone on heavy volume, which would invalidate the reversal setup entirely
- Negative company-specific news or broader market weakness — software and AI-adjacent names remain sensitive to risk-off rotations and any reassessment of AI-spend trajectories
- Government budget lumpiness — heavy reliance on public-sector funding can produce uneven quarterly results, as some federal contracts were already pushed from Q1 into Q2
- Regulatory and ethical scrutiny — Cellebrite’s forensic tools have periodically drawn human-rights criticism over their use in sensitive geopolitical regions, which can weigh on sentiment even when the company has tightened compliance
- Continued execution pressure on AI monetization — Genesis general availability arrives in mid-June, and the transition from free trials to paid usage has to convert at the rates the market is now pricing in
- Direct competition from Magnet Forensics and other emerging mobile-forensics and digital-investigation vendors, plus the constant arms race against rapidly evolving smartphone OS security
- Valuation premium — at $22.50 average analyst target versus a current price near $13, the bull case is well-known, leaving less room for incremental upgrades to drive the next leg
- Macro and geopolitical dependency — U.S. federal budget delays or Israel-related geopolitical risk (where Cellebrite has core operations) could pressure near-term deal flow
The Bottom Line
CLBT is pushing off the lower rail of a multi-month downtrend channel on the daily chart while holding a key resistance-turned-support level on the weekly — a dual-timeframe technical setup that historically signals the start of a sustained move higher.
The fundamental story underneath the chart is just as strong: a record Q1 2026 beat with ARR up 21% YoY, a landmark FedRAMP High federal authorization, and an agentic AI platform pulling 500+ users in eight weeks.
Combine that with multiple regulatory and commercial catalysts staggered through year-end — Genesis general availability, a dense investor-conference slate, federal traction commentary, and Q2 earnings — and CLBT looks like one of the more compelling risk-reward setups on the board right now.
If this is a trade you want to get in on, here’s how we’d play it. Below you’ll find our exact entry level, both price targets that imply 20%–30% potential upside, and the stop-loss we’re using to manage the downside.
Recommended Trade Setup
| Item | Detail |
|---|---|
| Buy Level | Above approximately $13.80 (daily close confirmation) |
| Price Target 1 | $16.50 — Potential upside: 20% |
| Price Target 2 | $18.00 — Potential upside: 30% |
| Timeframe | Next 3–6 months |
| Stop-Loss | $12.40 on a closing basis (below the support flip zone and weekly Parabolic SAR) |
If needed, swipe or scroll sideways to view the full table.
For a risk of approximately $1.40 per share, the target rewards are about $2.70 and $4.20 per share. That makes this roughly a 1:2 and 1:3 risk-reward trade. In other words, the setup offers nearly 2x to 3x more potential upside than downside.
Happy Trading!
Tara and Greg